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Available online 15 June 2012The interaction between the clonotypic αβ T cell receptor (TCR), expressed on the T cell
surface, and peptide-major histocompatibility complex (pMHC) molecules, expressed on the
target cell surface, governs T cell mediated autoimmunity and immunity against pathogens
and cancer. Structural investigations of this interaction have been limited because of the
challenges inherent in the production of good quality TCR/pMHC protein crystals. Here, we
report the development of an ‘intelligently designed’ crystallization screen that reproducibly
generates high quality TCR/pMHC complex crystals suitable for X-ray crystallographic studies,
thereby reducing protein consumption. Over the last 2 years, we have implemented this screen
to produce 32 T cell related protein structures at high resolution, substantially contributing to
the current immune protein database. Protein crystallography, used to study this interaction,
has already extended our understanding of the molecular rules that govern T cell immunity.
Subsequently, these data may help to guide the intelligent design of T cell based therapies that
target human diseases, underlining the importance of developing optimized approaches for
crystallizing novel TCR/pMHC complexes.
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T cells play an important role in the protection against
pathogens and cancer and have been shown to cause/
contribute towards many autoimmune diseases (Wong and
Pamer, 2003; Rudolph et al., 2006; Bulek et al., 2012). The T cell
receptor (TCR) recognizes foreign and self protein fragments
bound to the self-major histocompatibility complex (pMHC)
(Garboczi et al., 1996). The first structure of a murine TCR (2C)
with MHC class I H2-Kb in association with dEV8 peptide was
published in 1996 (Garcia et al., 1996). This was shortly
followed by the structure of a human TCR (A6) in complex
with HLA-A*0201-Tax (peptide derived from human T cell
lymphotropic virus type 111–19) (Garboczi et al., 1996). Theseah), coledk@cf.ac.uk
Y license. structures provided the first insight into T cell antigen
recognition and revealed a number of important features of
the interface between the TCR and pMHC. Ten years later, only
10 unique human TCR/pMHC complexes had been solved, as
reviewed by Rudolph et al. (2006). In recent years, this number
has increased to ~25 human TCR/pMHC complexes, but
progress has still been relatively slow compared with the
number of antibody structures, or unligated pMHC structures
that have been reported. This lack of structural information
regarding human TCR/pMHC complexes has compromised the
determination of a comprehensive and accepted set of rules
that govern T cell antigen recognition and a number of
conflicting theories still dominate the field (Bridgeman et al.,
2012).
Difficulties in generating sufficient quantities of soluble
TCR and pMHC protein, and in producing high quality TCR/
pMHC complex crystals, may explain the low number of
these structures. Additionally, TCRs bind to pMHCs with
relatively weak affinity (KD=0.1–300 μM (Cole et al., 2007;
Bridgeman et al., 2012)), which may further impede their
ability to form stable complexes for crystallization. A number
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stable, soluble recombinant TCRs, including modification of
the expression vectors and optimization of culture condi-
tions. To date, soluble TCRs have been generated using
various eukaryotic expression systems such as: Drosophila
melanogaster (Garcia et al., 1996), myeloma cells (Wang et
al., 1998), Chinese hamster ovary cells (Reiser et al., 2000)
and Spodoptera frugiperda cells (Hahn et al., 2005). However,
prokaryotic expression as inclusion bodies using Escherichia
coli strains, followed by artificial refolding, remains the most
popular and robust system because it produces high yields of
homogenous protein (Cole et al., 2007, 2008, 2009). Addition-
ally, four different TCR cloningmethods have been designed to
improve soluble TCR stability including: (1) expression of the
variable domains only in a form of a single chain Fv fragment
(scFv) (Housset et al., 1997); (2) expression of TCR α and β
chains carrying c-Jun (α) and c-Fos (β) leucine-zipper hetero-
dimerization motifs at their carboxyl termini (Garcia et al.,
1996); (3) introduction of a carboxy-terminal flanking se-
quence to the full length V and C ectodomains to promote the
formation of an interchain disulphide bridge (Stewart-Jones et
al., 2003); and, (4) introduction of a non-native disulphide
bond into the interface between the TCR constant domains
(Boulter et al., 2003). The ‘Boulter-disulphide’method has been
the preferred choice in our laboratory.
Once expressed and purified, the last challenge is to
generate TCR/pMHC complex protein crystals capable of high
resolution X-ray diffraction. In order to achieve this, a
number of commercial screens, not tailored specifically for
T cell associated proteins, have been used by different
laboratories with some success (evidenced by the modest
number of TCR/pMHC complexes published). Here we report
the development of a new crystallization screen specifically
designed for the production of high quality TCR, pMHC and
TCR/pMHC complex crystals suitable for crystallographic
studies. A wide selection of TCRs, pMHCs and TCR/pMHC
complexes, implicated in variety of diseases, were used to
test the efficacy of our screen. Using this novel approach, we
have been able to generate 32 crystal structures comprising:
21 TCR/pMHC complexes, 3 TCRs and 8 pMHCs, over the last
2 years. These structures have already enabled a better
understanding of T cell antigen recognition of viral (Miles et
al., 2010), autoimmune (Bulek et al., 2012) and cancer (Cole
et al., 2009) epitopes, as well as a number of so far
unpublished observations. Thus, our TCR/pMHC Optimized
Protein crystallization Screen (TOPS) will allow us, and
others, to investigate many important questions regarding
the molecular basis of T cell mediated immunity.
2. Materials and methods
2.1. Cloning and expression
The TCR α and TCR β chains, as well as the MHC class I α
chain and β2m sequences, were cloned into the pGMT7
expression vector under the control of the T7 promoter using
BamH1 and EcoR1 restriction sites as described previously
(Garboczi et al., 1992, 1996; Boulter et al., 2003). Sequences
were confirmed by automated DNA sequencing.
The TCRα and β chains, as well as HLA A*0201α chain and
β2m were expressed separately, without post-translationalmodification, as insoluble inclusion bodies (IBs) in competent
Rosetta DE3 E. coli cells as described previously (Garboczi et al.,
1992, 1996; Boulter et al., 2003).
2.2. Refolding and puriﬁcation
TCR refolding was performed as previously reported
(Miles et al., 2010). Briefly, for a 1 L TCR refold, 30 mg TCR
α-chain IBs was incubated at 37 °C for 15 min with 10 mM
DTT and added to cold refold buffer (50 mM TRIS, pH 8.1,
2 mM EDTA, 2.5 M urea, 6 mM cysteamine hydrochloride,
and 4 mM cystamine). After 15 min, 30 mg TCR β-chain IBs,
incubated at 37 °C for 15 min with 10 mM DTT, was added to
the same refold. For a 1 L pMHC class I refold, 30 mg HLA
A*0201 α-chain was mixed with 30 mg β2m and 4 mg
peptide at 37 °C for 15 min with 10 mM DTT. This mixture
was then added to cold refold buffer (50 mM TRIS, pH 8,
2 mM EDTA, 400 mM L-arginine, 6 mM cysteamine hydro-
chloride, and 4 mM cystamine). Refolds were mixed at 4 °C
for >1 h. Dialysis was performed against 10 mM TRIS, pH 8.1,
until the conductivity of the refolds was less than two
millisiemens per centimeter. The refolds were then filtered,
ready for purification steps.
Refolded proteins were purified initially by ion exchange
using a Poros50HQ™ column (GE Healthcare, Buckingham-
shire, U.K.) and finally gel filtered into a crystallization buffer
(10 mM TRIS pH 8.1 and 10 mM NaCl) using a Super-
dex200HR™ column (GE Healthcare, Buckinghamshire,
U.K.). Protein quality, either under non-reducing or reducing
conditions, was analyzed by Coomassie-stained SDS-PAGE.
2.3. Protein crystallization
Crystals were grown at 18 °C by vapor diffusion via the
sitting drop technique. All crystallization screening and
optimization experiments were completed with an Art-
Robbins Phoenix dispensing robot (Alpha Biotech Ltd, U.K.).
200 nL of 10–20 mg/ml TCR, pMHC, or TCR and pMHC
complex mixed at a 1:1 molar ratio, was added to 200 nL of
reservoir solution. Intelli-plates were then sealed and
incubated in a crystallization incubator (18 °C) (Molecular
Dimensions) and analyzed for crystal formation. Crystals
selected for further analysis were cryoprotected with 25%
ethylene glycol and then flash cooled in liquid nitrogen in
Litho loops (Molecular Dimensions).
2.4. Structure determination and reﬁnement
Diffraction data was collected at a number of different
beamlines at the Diamond Light Source, Oxford, using a
Pilatus 2M, or a QADSC, detector. Using a rotation method,
400 frames were recorded each covering 0.5° of rotation.
Reflection intensities were estimated with the XIA2 package
(Winter, 2010) and the data were scaled, reduced and
analyzed with SCALA and the CCP4 package (Collaborative
Computational Project, N, 1994). The TCR, pMHC, or TCR/
pMHC complex structures were solved with molecular
replacement using PHASER (McCoy et al., 2005), or AMORE
(Trapani and Navaza, 2008). The model sequences were
adjusted with COOT (Emsley and Cowtan, 2004) and the
models refined with REFMAC5.
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3.1. Design of a TCR/pMHC Optimized Protein crystallization
Screen (TOPS)
TCR/pMHC complex structures have previously been
solved by a number of different groups using individually
determined crystallization conditions. In order to combine
these data to generate a comprehensive TCR/pMHC Opti-
mized Protein crystallization Screen (TOPS), we investigated
the crystallization conditions of 16 previously published TCR/
pMHC complexes (Garboczi et al., 1996; Garcia et al., 1996;
Ding et al., 1998, 1999; Hennecke et al., 2000; Reiser et al.,
2000, 2003; Hennecke and Wiley, 2002; Kjer-Nielsen et al.,
2003; Stewart-Jones et al., 2003; Chen et al., 2005; Li et al.,
2005; Maynard et al., 2005; Tynan et al., 2005, 2007; Sami et
al., 2007; Cole et al., 2009) (Fig. 1). Although there was a
substantial variation in the crystallization conditions identi-
fied for different TCR/pMHC complexes, we noticed certainFig. 1. Analysis of the crystallization conditions of 16 previously published TCR/pM
preference for the higher end of this pH range. (B) Glycerol was used as a cryo-protect
to 8000 g/mol (PEG 3350, 4000 and 8000 being the most successful). (D) The best PEG
10%–25%. (E) Various salts, with concentrations from 0–1 M, were used, with a prefetrends. The pH lay between 5.6–8.5 in all cases, with the TCR/
pMHC complexes tending to crystallize at the higher end of
this pH range (Fig. 1A); with 25%, 19% and 19% of complexes
crystallizing in the pH range of 7.0–7.5, 7.5–8.0 and 8.0–8.5,
respectively. Six conditions (38%) contained glycerol as
cryoprotectant (Fig. 1B). All conditions contained PEG (polyeth-
ylene glycol), although the weight (550–8000 g/mol) and
percentage (10–25%) were very variable. The best PEG
concentration, representing 31% of the previous structures
reported, was between 15%–17.5%. Molecular weight PEG
3350, 4000 and 8000 were most successful (Fig. 1C and D)
evidenced by 31%, 13% and 44% of all structures being obtained
with each additive, respectively. Another common component
of successful conditionswere various salts, with concentrations
ranging from 0–1 M, the absence of salt (38%) and 0.2 M (31%)
being most popular (Fig. 1E).
Based on these findings we developed a crystallization
screen for TCR/pMHC complexes (Tables 1A and 1B). Our
screen consisted of two 48 well PEG/pH screens. Each PEG/pHHC complexes. (A) The pH of the conditions lay between pH 5.6–8.5, with a
ant in 38% of cases. (C) The molecular weight of the PEG varied from 550 g/mol
concentration was between 15%–17.5%, with a PEG concentration range from
rence for 0.2 M.
Table 1A
TOPS screen conditions 1–48.
Buffer (pH) (0.1 M) PEG 4000 PEG 8000
15% 20% 25% 15% 20% 25%
C2H6AsO2Na (pH 6) A1 A2 A3 A4 A5 A6
C2H6AsO2Na (pH 6.5) B1 B2 B3 B4 B5 B6
MES (pH 7) C1 C2 C3 C4 C5 C6
HEPES (pH 7) D1 D2 D3 D4 D5 D6
HEPES (pH 7.5) E1 E2 E3 E4 E5 E6
TRIS (pH 7.5) F1 F2 F3 F4 F5 F6
TRIS (pH 8) G1 G2 G3 G4 G5 G6
TRIS (pH 8.5) H1 H2 H3 H4 H5 H6
All conditions contained 15% glycerol.
Table 1B
TOPS screen conditions 49–96.
Buffer (pH) (0.1 M) PEG 4000 PEG 8000
15% 20% 25% 15% 20% 25%
C2H6AsO2Na (pH 6) A7 A8 A9 A10 A11 A12
C2H6AsO2Na (pH 6.5) B7 B8 B9 B10 B11 B12
MES (pH7) C7 C8 C9 C10 C11 C12
HEPES (pH 7) D7 D8 D9 D10 D11 D12
HEPES (pH 7.5) E7 E8 E9 E10 E11 E12
TRIS (pH 7.5) F7 F8 F9 F10 F11 F12
TRIS (pH 8) G7 G8 G9 G10 G11 G12
TRIS (pH 8.5) H7 H8 H9 H10 H11 H12
All conditions contained 0.2 M (NH4)2SO4.
Table 2











1E6/A2-ALW TOPS 2.6 6.0 15 4000 15 0
1E6/A2-AQW PACT 3.0 6.5 20 4000 0 0.2
1E6/A2-RQW PACT 2.3 6.0 20 6000 0 0.2
1E6/A2-YQF PACT 2.1 7.0 20 6000 0 0.2
1E6/A2-WQY TOPS 1.9 7.0 25 8000 0 0.2
1E6/A2-KLP TOPS 2.9 6.5 15 8000 0 0.2
1E6/A2-YLG TOPS 2.5 6.5 15 4000 0 0.2
1E6/A2-MVW TOPS 2.0 7.5 15 4000 0 0.2
1E6/A2-RQF(I) TOPS 1.9 7.5 15 4000 0 0.2
1E6/A2-RQF(A) TOPS 1.9 7.0 15 4000 0 0.2
GP100/A2-YLE JBS 2.0 7.0 20 4000 0 0.2
ILA/A2-ILA TOPS 2.6 7.0 20 8000 0 0.2
AS01/A2-GLC TOPS 2.6 6.0 20 4000 0 0.2
α24β17/A2-ELA TOPS4 2.4 7.0 20 4000 0 0.2
α24β17/A2-AAG TOPS 2.8 7.0 20 4000 15 0
α24β17/A2-ELA-4A TOPS3 2.7 7.0 15 4000 17.4 0
α24β17/A2-ELA-7A TOPS4 2.6 7.0 20 4000 17.4 0.2
α24β17/A2-EAA TOPS4 2.1 7.5 15 4000 8.7 0.2
MEL5/A2-EAA TOPS 3.0 6.5 15 4000 15 0
MEL5/A2-AAG TOPS 3.2 7.5 25 4000 15 0
P1/A2-CLG TOPS 2.6 6.0 15 4000 15 0
SB7/A2-FLY TOPS 2.6 6.5 15 4000 0 0.2
868/A2-SLY TOPS 2.9 6.0 15 4000 0 0.2
868/A2-6I TOPS 2.9 6.0 15 4000 0 0.2
868/A2-3F6I8V TOPS1 2.8 5.5 15 4000 0 0.2
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HEPES and TRIS) at a concentration of 0.1 M in combination
with PEG 4000, or PEG 8000 at 15, 20 and 25%. These buffers
allowed scanning the pH range from 6.0–8.5. 15% glycerol
was added to the first subscreen (Table 1A), whereas 0.2 M
ammonium sulfate was added to the second subscreen
(Table 1B).
In some cases, TOPS generated several crystal hits that were
of lower quality, i.e. the crystals were very small, contained
cracks or impurities, or did not diffract to high resolution. In
these cases, we extended the conditions that yielded crystals to
generate a number of other fine screens that proved useful for
specific TCR/pMHC complexes. TOPS1 (Supplementary Table 1)
was designed by extending the lower range of pH with
C2H6AsO2Na pH 5.0 and 5.5 of the A07 condition of the TOPS
screen. In addition, PEG 3350 was compared versus PEG 4000
in this screen. TOPS2 (Supplementary Table 2) was designed by
extending the lower range of PEG concentration (10, 12.5, 15,
17.5, 20 and 22.5%) of the second subscreen of the TOPS screen.
In addition, one of the buffer systems (C2H6AsO2Na pH 6.0)
was replaced by a non-buffered condition and supplemented
by another precipitant (0.2 M sodium sulfate) as some good
hits were obtained using a commercially available screen
(PACTPremier, condition E08; 0.2 M sodium sulfate and 20%
PEG 4000). TOPS3 (Supplementary Table 3) was designed by
reducing the range of pH (from 6.5–7.5) and increasing the
number of buffer system (MES pH 6.5, BIS TRIS propane pH 7.0
and TRIS pH 7.0) as well as the range of glycerol concentrations
(0, 4.4, 8.7 and 17.4%). PEG 4000 was the PEG of choice in this
screen. The only difference between TOPS3 and TOPS4(Supplementary Table 4) was that TOPS4 contained 0.2 M
ammonium sulfate. These screens generated 5 TCR/pMHC
complexes as detailed in Table 2.3.2. Optimal conditions for the generation of TCR/pMHC complex
crystals
High-throughput crystallization trials were performed
using 3 commercially available screens (PACT Premier,
JBScreen and JCSG-plus (Molecular Dimensions Ltd, Suffolk,
U.K.)) and/or 5 different “homemade” screens (TOPS, TOPS1,
TOPS2, TOPS3 and TOPS4) (Tables 1A and 1B, Supplementary
Tables 1–4), the last four screens being derivatives of the TOPS
screen. Crystallization conditions were successfully identified
for 25 TCR/pMHC complexes, 14 of which were derivatives
from a common parent complex. Among these 25 unique
complexes, 21 were obtained from the TOPS screen or TOPS
screen-derived conditions while only 3 were obtained from
the PACT Premier screen and 1 from the JBScreen. No
complexes were obtained from the JCSG-plus screen. Thus,
TCR/pMHC structures that crystallized in TOPS screen repre-
sented more than 80% of the total number of complexes solved
(Table 2).
Although the TOPS screen was designed for TCR/pMHC
complexes, a selection of uncomplexed TCR and pMHC
proteins were generated based on our ongoing research
interests, to test the efficacy of TOPS. This approach directly
resulted in structures of 3 uncomplexed TCR and 8 pMHC
proteins. The total number of 25 complexes and 53 datasets
(we often collected several datasets from different conditions
for a particular complex) allowed us to perform an analysis in
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crystals of TCR/pMHC complexes.
Crystallization conditions are presented in Fig. 2. In all
cases, the pHwaswithin a range of 5.0–8.5. However, the great
majority of crystals (90%) were obtained around a neutral pH
of 6.0–7.5, and more than a third (35%) at pH 7.0 (Fig. 2A). The
presence of salt, a precipitating agent, at 0.2 M was required as
79% of crystals successfully grew in such conditions (Fig. 2B).
The best PEG concentrations, another precipitating agent, were
15% and 20%, resulting in 51% and 40% of the datasets,
respectively. In contrast, higher precipitant concentrations
produced only 9% of the datasets (Fig. 2C). The most popular
PEG size was around 4000 g/mol with 79% of datasets obtained
in this condition (13% PEG 3350 and 66% PEG 4000). PEG at
smaller molecular weight only generated 2% of the datasets,
whereas PEG at higher molecular weight generated 19% of the
datasets (6% and 13% of PEG 6000 and 8000 respectively)
(Fig. 2D). Although glycerol was a good cryoprotecting agent,
the absence of this component was essential in 72% of theFig. 2. Analysis of crystallization conditions obtained from 25 TCR/pMHC complexes
around a neutral pH from 6.0–7.5. (B) The presence of 0.2 M salt was required in
representing 91% of the datasets. (D) The most popular PEG molecular weight was a
PEG 4000). (E) The absence of glycerol was dominant (72%), but the best concentrcases. However, when the presence of glycerol was required,
15% appeared to be the best concentration (Fig. 2E).
Although this analysis suggested the optimal conditions for
obtaining TCR/pMHC complexes, it was performed by taking
each variable independently. In order to verify if a given
condition was more representative than the others, the
frequency of appearance of each particular condition was
calculated (Fig. 3). The conditions producing less than 5% of the
datasets were combined together. This combined fraction of 23
different conditions correlated to 51% of all datasets. The
remaining 6 conditions (pH 6.5 20% PEG 3350 0.2 M salt, pH
6.0 15% PEG 4000 0.2 M salt, pH 6.5 15% PEG 4000 0.2 M salt,
pH 7.0 15% PEG 4000 0.2 M salt, pH 7.5 15% PEG 4000 0.2 M
salt and pH 7.0 20% PEG 4000 0.2 M salt), surprisingly,
produced nearly half of all datasets (Fig. 3). This analysis
completely correlated with the previous independent analysis
with a pH range from 6.0–7.5, a required presence of 0.2 M salt,
a preferred PEG size around 4000 g/mol and PEG concentra-
tions of 15% and 20%. Based on these analyses, it could be. (A) The pH was within a range of 5.0–8.5, with 91% of the datasets obtained
79% of the conditions. (C) The best PEG concentrations were 15% and 20%,
round 4000 g/mol, representing 79% of the datasets (13% PEG 3350 and 66%
ation of glycerol when this component was required was 15%.
Fig. 3. Analysis of the frequency of appearance of a particular condition. The conditions producing less than 5% of the datasets were combined together. The 53 datasets
were obtained in a total of 29 different conditions. Among these 29 conditions, 6 conditions (pH6.5 20% PEG 33500.2 M salt, pH6.0 15% PEG 40000.2 M salt, pH6.5 15%
PEG 4000 0.2 M salt, pH 7.0 15% PEG 4000 0.2 M salt, pH 7.5 15% PEG 4000 0.2 M salt and pH 7.0 20% PEG 4000 0.2 M salt) produced nearly half of all datasets.
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for TCR/pMHC complexes. However, further analysis revealed
that, although the vast majority of TCR/pMHC complexes
crystallized within the remit of these conditions, a number of
structures crystallized in conditions outside of this range
(Fig. 4). Thus, although it could be tempting to limit the
number of conditions in a protein crystal screen to improve
efficiency and reduce protein consumption, broader screens
are required to ensure that crystallization conditions are not
missed for important proteins.
4. Discussion
The ability of T cells to respond to antigen depends on the
productive interaction between the TCR and pMHC. The crystal
structures of a number of TCR/pMHC complexes have been
solved and show that the TCR has a relatively conserved modeFig. 4. Representation of the expected TOPS efficiency correlated to the datasets obta
scoring system related to the percentage of datasets obtained per condition of pH,
system allows us to generate a score for each condition of TOPS based on the num
scores b2.5 in dark blue, 2.5–5 in light blue, 5–7.5 in green, 7.5–10 in yellow, 10–12.
The vast majority of TCR/pMHC complexes crystallized in the conditions with a high
system.of binding to pMHC in which the TCR lines up approximately
diagonally to the MHC peptide binding groove, with the TCR α
chain contacting the MHC α2 domain and the TCR β chain
contacting the MHC α1 domain. The antigen specific portion of
the TCR/pMHC interaction occurs between the pMHC surface
and the TCR complementarity determining region loops (CDR-
loops) (Rudolph et al., 2006). These CDR-loops serve different
roles during TCR binding to pMHC: the variable (V)-gene
encoded CDR2-loops contact mainly the conserved helical
region of theMHC surface, the V-gene encoded CDR1-loops can
contact both the MHC and the peptide and the more variable
somatically rearranged CDR3-loops contact mainly the anti-
genic peptide. Although the general features of TCR/pMHC
binding have been defined, there remains a number of
conflicting models that describe the structural basis of T cell
MHC-restriction, cross-reactivity, autoimmunity and alloreac-
tivity. Furthermore, each previous TCR/pMHC complex hasined with that screen. Based on the analysis presented in Fig. 2, we designed a
PEG concentration, PEG size and the presence of salt or glycerol. This scoring
ber of TCR/pMHC complexes crystallized in each condition. We represented
5 in orange and >12.5 in red. Each dark circle represents a successful dataset
score, but a number of complexes crystallized in the low range of this scoring.
209A.M. Bulek et al. / Journal of Immunological Methods 382 (2012) 203–210been governed by a unique set of contacts that enable T cell
antigen recognition. Thus, there is still a pressing need to
increase the number of TCR/pMHC complex structures in the
literature in order to: (1) determine an accepted set of rules
that describe the generalities of T cell specificity, and (2) under-
stand the unique features of individual TCR/pMHC interactions
that allow T cells to target different disease epitopes.
The study of TCR/pMHC complexes has been limited by the
challenges in expression, purification and successful crystalli-
zation of these soluble proteins. Here, we report a new
systematic and directed approach for the design of a TCR/
pMHC Optimized Protein crystallization Screen (TOPS) that has
proved to be useful for the crystallization of this family of
immuno-proteins. With this novel crystallization screen, we
have successfully generated the majority of our current
portfolio of structures that includes 21 TCR/pMHC complexes
(13 derived from a common parent complex), 3 TCRs and
8 pMHCs. We found that TCR/pMHC complex crystals most
commonly formed at a neutral pH, with 15%–20% of PEG 4000
and 0.2 M ammonium sulfate. In addition, results from our
crystallization trials indicated that it may be possible to
significantly restrain the crystallization conditions of TCR/
pMHC complexes to around 6 different conditions (rather
than 96). Although this could substantially reduce the quantity
of protein required for the successful generation of TCR/pMHC
complex crystals capable of diffracting to high resolution, our
analyses revealed that a limited screen could exclude some
important crystallization conditions for some proteins. Thus,
our TOPS screen remains optimal for the crystallization of TCR/
pMHC complexes.
In conclusion, we hope that TOPS will greatly contribute to
a better understanding of molecular basis for T cell recognition
of self, foreign (microbial/viral/parasitic) and autoimmune
antigens by providing an improved method for generating
TCR/pMHC complex protein crystals capable of high quality X-
ray diffraction. Furthermore, we expect that TOPSwill be useful
for the determination of TCR structures in complex with
classical and non-classical MHC ligands that are less well
characterized, including: pMHC class II, MR1, CD1c and HLA-E.
Structural information, detailing the precise atomic contacts
that mediate T cell immunity, can provide clear insights into
various immune dysfunctions and could accelerate the rational
design of T cell based therapies and vaccines.Author contributions
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